跳至主要内容
临床试验/NCT00693927
NCT00693927已完成2 期

Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Phase II Trial

University of Liege2 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2002年3月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
54
试验地点
2
主要终点
Incidence of acute GVHD in CD8-depleted versus unmanipulated groups

研究概览

简要总结

Prospective randomized study of allogeneic minitransplantation from HLA-identical family or unrelated donors comparing unmanipulated or CD8-depleted PBSC. The conditioning regimen will be 2 Gy TBI alone (related donor with low-risk of transplant rejection) or 2 Gy TBI and 3 x 30 mg/m2 fludarabine (unrelated donor or high risk of transplant rejection). Patients will receive a short but intensive immunosuppressive treatment (cyclosporine and mycophenolate mofetil) to ensure both graft-versus-host and host-versus-graft tolerance. The rationale for using PBSC instead of marrow transplant is to avoid general anesthesia of the donor and to minimize the risk of rejection. The rationale for CD8+ depletion is to diminish the risk of GVHD after PBSC transplantation or DLI.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Incidence of acute GVHD in CD8-depleted versus unmanipulated groups

时间窗: 180 days

Incidence of chronic GVHD (overall and extensive) in CD8-depleted versus unmanipulated groups.

时间窗: 1-year

次要结局

  • Incidence of graft rejection [according to the risk of transplant rejection (see table 1 above)] in CD8-depleted versus unmanipulated groups.(1-year)
  • T cell (CD3) and myeloid (CD13) chimerism in CD8-depleted versus unmanipulated groups.(1-year and then long term)
  • Quality and timing of immune reconstitution in CD8-depleted versus unmanipulated groups.(1-year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Yves Beguin

Prof

University of Liege

研究点 (2)

Loading locations...

相似试验